Related Experiment Video
Updated: May 14, 2026

A Visual Approach for Inducing Dolichoectasia in Mice to Model Large Vessel-Mediated Cerebrovascular Dysfunction
Published on: May 17, 2024
Temporal intradiploic dilative vasculopathy: an additional pathogenic factor for the hearing loss in fabry disease?
Carla Pinto Moura1, Carlos Soares, Daniela Seixas
1Department of Otolaryngology, Faculty of Medicine, University of Porto and Hospital São João, Alameda Hernâni Monteiro, 4200-319, Porto, Portugal, cmoura@med.up.pt.
Insights
Fabry disease (FD) can cause progressive hearing loss. New research suggests unusual blood vessel changes in the temporal bone may contribute to hearing damage in FD patients, even with treatment.
Area of Science:
- Neurology
- Genetics
- Otolaryngology
Background:
- Fabry disease (FD) results from lysosomal α-galactosidase deficiency, leading to glycosphingolipid accumulation.
- Otological symptoms like progressive sensorineural hearing loss (HL), tinnitus, and dizziness are common in FD.
Purpose of the Study:
- To investigate the potential contribution of vascular abnormalities in the temporal bone to progressive hearing loss in a patient with Fabry disease.
- To highlight the importance of comprehensive neuroimaging in managing hearing loss in FD.
Main Methods:
- Case study of a 45-year-old male with FD undergoing enzyme replacement therapy (ERT).
- Audiological evaluation, computed tomography (CT) of the ears, and magnetic resonance angiography (MRA) were performed.
- Follow-up audiological assessments documented hearing changes over time.
Main Results:
- The patient exhibited bilateral sloping sensorineural HL, worsening despite high-dose ERT.
- CT revealed enlarged intradiploic vascular channels in the petrous bone.
- MRA showed arterial elongation and ectasia in the Circle of Willis.
- These vascular abnormalities in the temporal bone are novel findings in FD.
Conclusions:
- Intradiploic vascular abnormalities in the temporal bone may contribute to progressive HL in FD via a 'stealing' effect on cochlear blood supply.
- Comprehensive neuroimaging is valuable for investigating HL in FD patients.
- Early therapeutic intervention is crucial to prevent irreversible inner ear damage.
Abstract:
Fabry disease (FD) is caused by progressive accumulation of neutral glycosphingolipids, including in ganglion neural and vascular endothelial cells, as a result of lysosomal α-galactosidase deficiency. High frequencies progressive sensorineural hearing loss (HL), sudden deafness, tinnitus and dizziness are otological symptoms frequently reported.A 45-year-old man with FD, on haemodialysis since age 25, complaining of progressive HL, was started on enzyme replacement therapy (ERT) because of cardiac complications. A bilateral sloping sensorineural HL was found at baseline audiological evaluation. Computed tomography of the ears showed enlargement of the intradiploic vascular channels, principally in the petrous bone. The magnetic resonance angiography showed elongation and ectasia of the middle cerebral arteries and the arteries of the Circle of Willis, particularly the internal carotid and the basilar arteries. Follow-up audiological evaluations documented progressive worsening of HL, mainly in the high frequencies range, despite high dose ERT and evidence of cardiac improvement.The intradiploic vascular abnormalities of the temporal bones reported herein have never been described in association with FD and may have contributed to the pathogenesis of progressive HL, by a 'stealing' effect upon the cochlear blood supply (like in cavernous haemangioma of the internal auditory meatus), in addition to the other mechanisms of ischaemic injury to the Organ of Corti described in FD. This clinical observation shows the value of comprehensive neuroimaging investigation of HL in FD and emphasizes the importance of early institution of specific therapy, before the occurrence of irreversible inner ear lesions and hearing damage.
Related Concept Videos
Diabetic Retinopathy
Heart Failure II: Pathophysiology
Cardiomyopathy II: Dilated Cardiomyopathy
Rheumatic Heart Disease I: Introduction

